498 related articles for article (PubMed ID: 23448791)
1. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
2. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro.
Vos AC; Wildenberg ME; Arijs I; Duijvestein M; Verhaar AP; de Hertogh G; Vermeire S; Rutgeerts P; van den Brink GR; Hommes DW
Inflamm Bowel Dis; 2012 Mar; 18(3):401-8. PubMed ID: 21936028
[TBL] [Abstract][Full Text] [Related]
3. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
Tang R; Yang G; Zhang S; Wu C; Chen M
Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
7. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease.
Ogino T; Nishimura J; Barman S; Kayama H; Uematsu S; Okuzaki D; Osawa H; Haraguchi N; Uemura M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Takeda K; Doki Y; Mori M
Gastroenterology; 2013 Dec; 145(6):1380-91.e1. PubMed ID: 23993972
[TBL] [Abstract][Full Text] [Related]
8. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease.
Su J; Chen T; Ji XY; Liu C; Yadav PK; Wu R; Yang P; Liu Z
Inflamm Bowel Dis; 2013; 19(4):720-8. PubMed ID: 23429464
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease.
Nielsen OH; Kirman I; Rüdiger N; Hendel J; Vainer B
Scand J Gastroenterol; 2003 Feb; 38(2):180-5. PubMed ID: 12678335
[TBL] [Abstract][Full Text] [Related]
10. Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action.
Petito V; Lopetuso LR; Arena V; Stigliano E; Boninsegna A; Bibbò S; Poscia A; Alfieri S; Rosa F; Amato A; Cammarota G; Papa A; Sgambato A; Gasbarrini A; Scaldaferri F
Dig Liver Dis; 2016 Apr; 48(4):391-8. PubMed ID: 26804809
[TBL] [Abstract][Full Text] [Related]
11. Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease.
Franzè E; Caruso R; Stolfi C; Sarra M; Cupi ML; Caprioli F; Monteleone I; Zorzi F; De Nitto D; Colantoni A; Biancone L; Pallone F; Monteleone G
PLoS One; 2013; 8(7):e69839. PubMed ID: 23922818
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn's disease.
Neves AR; Castelo-Branco MT; Figliuolo VR; Bernardazzi C; Buongusto F; Yoshimoto A; Nanini HF; Coutinho CM; Carneiro AJ; Coutinho-Silva R; de Souza HS
Inflamm Bowel Dis; 2014 Mar; 20(3):444-57. PubMed ID: 24412990
[TBL] [Abstract][Full Text] [Related]
14. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity.
Liu Z; Yadav PK; Xu X; Su J; Chen C; Tang M; Lin H; Yu J; Qian J; Yang PC; Wang X
J Leukoc Biol; 2011 Apr; 89(4):597-606. PubMed ID: 21227898
[TBL] [Abstract][Full Text] [Related]
15. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease.
Woywodt A; Ludwig D; Neustock P; Kruse A; Schwarting K; Jantschek G; Kirchner H; Stange EF
Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):267-76. PubMed ID: 10333199
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
Zhou L; Chen H; Wen Q; Zhang Y
Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):695-701. PubMed ID: 22387885
[TBL] [Abstract][Full Text] [Related]
17. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ
Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
[TBL] [Abstract][Full Text] [Related]
20. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
